(Total Views: 563)
Posted On: 01/09/2023 11:13:15 AM
Post# of 148870
Re: biloxiblues #132284
Thank you for your excellent analysis, bilo!
I wonder if the Amarex sabotage of leronlimab in the time of a national emergency may be presented as a possible conspiracy and a case for an FBI probe?
"Amarex attempted to squash CytoDyn with their shady attempt of sabotage, by botching the collection of CytoDyn's data and improperly recording that data while purposefully filling out fields incorrectly or leaving those fields blank. And when CytoDyn confronted Amarex for that data, Amarex refused to yield it to the rightful owner, CytoDyn. Amarex, led by their CEO Kazem, was crafty, doing all their dirtywork in secret and they kept their forgery as a clandestine as long as they could. Amarex's intention was to cut CytoDyn off from being a pharmaceutical and to cut off Leronlimab from being an approved drug for HIV MDR indication. That is because, once it would be approved for this indication and once patients were to see how easy it is to administer, and how infrequent and with so few side effects, it could be prescribed off label for nearly anything else. So of course, Amarex was promised some very good future prospects if they would only botch this trial against CytoDyn. If they would just ruin this BLA so that it would not be acceptable to the FDA. And that is what they did. This professional CRO forgot who they were and recorded the data for this trial as if they were kindergarteners. Their CEO Kaz, being bought and paid for."
Read More: https://investorshangout.com/post/view?id=652...z7pufbQERj
I wonder if the Amarex sabotage of leronlimab in the time of a national emergency may be presented as a possible conspiracy and a case for an FBI probe?
"Amarex attempted to squash CytoDyn with their shady attempt of sabotage, by botching the collection of CytoDyn's data and improperly recording that data while purposefully filling out fields incorrectly or leaving those fields blank. And when CytoDyn confronted Amarex for that data, Amarex refused to yield it to the rightful owner, CytoDyn. Amarex, led by their CEO Kazem, was crafty, doing all their dirtywork in secret and they kept their forgery as a clandestine as long as they could. Amarex's intention was to cut CytoDyn off from being a pharmaceutical and to cut off Leronlimab from being an approved drug for HIV MDR indication. That is because, once it would be approved for this indication and once patients were to see how easy it is to administer, and how infrequent and with so few side effects, it could be prescribed off label for nearly anything else. So of course, Amarex was promised some very good future prospects if they would only botch this trial against CytoDyn. If they would just ruin this BLA so that it would not be acceptable to the FDA. And that is what they did. This professional CRO forgot who they were and recorded the data for this trial as if they were kindergarteners. Their CEO Kaz, being bought and paid for."
Read More: https://investorshangout.com/post/view?id=652...z7pufbQERj
(0)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
